CAJ | 학술논문

目的探讨CT引导下经皮穿刺125I粒子植入治疗晚期肺癌的可行性、疗效及并发症情况.方法根据治疗方法的不同,将65例晚期肺癌患者分为2组,单纯植入粒子组37例,行单纯CT引导下125I粒子植入治疗；联合组28例,行125I粒子植入治疗联合泽菲和顺铂化疗,两组患者术后均行剂量学验证,并定期随访复查.结果 65例患者术后总有效率为80.0％,1年生存率为90.8％,单纯植入粒子组与联合组的有效率分别为67.6％和96.4％,两组之间差异有统计学意义(x2=8.298,P＜0.01).所有患者治疗前肿瘤平均直径为5.48 cm,治疗后为3.77 cm,治疗前、后差异有统计学意义(t=7.764,P＜0.01).65例患者术后36例出现气胸,7例出现血痰,4例出现发热,对症处理后均好转；未出现放射性肺炎等.结论 125I粒子植入治疗晚期肺癌的近期疗效肯定,无严重并发症.
목적 탐토CT인도하경피천자125I입자식입치료만기폐암적가행성、료효급병발증정황.방법 근거치료방법적불동,장65례만기폐암환자분위2조,단순식입입자조37례,행단순CT인도하125I입자식입치료；연합조28례,행125I입자식입치료연합택비화순박화료,량조환자술후균행제량학험증,병정기수방복사.결과 65례환자술후총유효솔위80.0％,1년생존솔위90.8％,단순식입입자조여연합조적유효솔분별위67.6％화96.4％,량조지간차이유통계학의의(x2=8.298,P＜0.01).소유환자치료전종류평균직경위5.48 cm,치료후위3.77 cm,치료전、후차이유통계학의의(t=7.764,P＜0.01).65례환자술후36례출현기흉,7례출현혈담,4례출현발열,대증처리후균호전；미출현방사성폐염등.결론 125I입자식입치료만기폐암적근기료효긍정,무엄중병발증.
Objective To investigate the feasibility,efficacy and complications of CT guided radioactive 125I seed implantation in the treatment of lung cancer.Methods According to the different treatment methods,65 patients with lung cancer were divided into two groups,37 cases in the implantation alone group received CT guided 125I seeds interstitial implantation,the other 28 cases in the combination treatment group received interstitial 125I seeds implantation combined with chemotherapy.All the patients were examined by posologic validation,and were followed up termly.Results The total effictive rate of 65 patients was 80.0％,1-year survival rate was 90.8％.The effictive rates of implantation alone group and combination treatment group were 67.6％ and 96.4％ respectively.There was a significant difference between the two groups (x2=8.298,P＜0.01).Before treatment,all the patients' mean diameter of the tumor was 5.48 cm; while it was 3.77 cm after treatment (t=7.764,P＜0.01).Complications included pneumothorax (36 cases),bloody sputum (7 cases),fever (4 cases) which improved after treatment in 65 patients,but without radiation pneumonia.Conclusion 125I seed implantation is a highly effective treatment without severe complications in the treatment of lung cancer.